3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Colorectal Neoplasms
38
Stomach Neoplasms
24
Rectal Neoplasms
19
Pancreatic Neoplasms
17
Lymphoma, Large B-Cell, Diffuse
14
Colonic Neoplasms
14
Esophageal Neoplasms
12
Adenocarcinoma Of Esophagus
12
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
9
Neoplasm Metastasis
9
Adenocarcinoma
9
Cholangiocarcinoma
8
Biliary Tract Neoplasms
6
Ovarian Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Hepatocellular
4
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Lung Neoplasms
3
Gallbladder Neoplasms
3
Endometrial Neoplasms
3
Carcinoma
3
Bile Duct Neoplasms
3
Advanced Solid Tumors
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Spinocerebellar Degenerations
2
Recurrence
2
Interventions
Rituximab
25
Lenalidomide
21
Cyclophosphamide
20
Prednisone
14
obinutuzumab
12
Vincristine
12
Doxorubicin
11
Magnetic Resonance Spectroscopy
10
Bendamustine Hydrochloride
9
Specimen Handling
8
ibrutinib
7
Biopsy
7
fludarabine
6
pembrolizumab
5
fludarabine phosphate
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
zanubrutinib
4
venetoclax
4
tazemetostat
4
Whole-Body Irradiation
4
R-CHOP protocol
4
Prednisolone
3
Mycophenolic Acid
3
Etoposide
3
Cyclosporine
3
tisagenlecleucel
2
polatuzumab vedotin
2
orelabrutinib
2
loncastuximab tesirine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
Oxaliplatin
×
90 days
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled